drugset / Trial / NCT01790022
Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL)
Phase 2
Unknown
20 enrolled
Saratov State Medical University
Charite University, Berlin, Germany · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, efficacy of methylprednisolone in reduction of signs and symptoms (back pain, stiffness, joint pain and swelling) of active ankylosing spondylitis (AS) will be investigated. It is expected, that a single dose of methylprednisolone 500 mg given intravenously at baseline will lead to a rapid reduction of symptoms of active AS, which can be seen already 2 weeks after drug administration.
Timeline
- Start
- 2012-07
- Primary completion
- 2013-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylprednisolone | Other / unclassified | 500 mg | Intravenous |